Ulcerative Colitis Infusion Therapy | ENTYVIO (vedolizumab)

Click UC (ulcerative colitis) or CD (Crohn's disease) to change the selected condition.

Your healthcare provider will administer ENTYVIO through a needle placed in a vein (IV infusion) in your arm, either at their office, at an infusion center, or in your home. Infusions last approximately 30 minutes. During and after the infusion, your healthcare provider will monitor you for side effects to see if you have a reaction to the treatment.

ENTYVIO is a biologic medicine that is administered intravenously (IV). After a 6-week starting period, you'll receive maintenance doses every 8 weeks.

Learn more about the treatment plan below.

You will receive starting doses of ENTYVIO 300mg by infusion at Weeks 0, 2, and 6. The infusion takes about 30 minutes.

After you complete your starting doses, you'll get one 30-minute infusion every 8weeks to help keep your disease under control.

In the first year, you'll receive 8 doses of ENTYVIO, each infused over 30 minutesfor a total infusion time of approximately 4 hours.

After the first year, you will receive 6 infusions per year. That's about 3 total hours per year.

Talk with your doctor and insurance provider to determine which locations work best for you.

Please see the full Prescribing Information, including the Medication Guide, for ENTYVIO and talk with your healthcareprovider.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch or call 1-800-FDA-1088.

ENTYVIO is a prescription medicine used in adults for the treatment of:

Please see the full Prescribing Information, including the Medication Guide, for ENTYVIO and talk with your healthcareprovider.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch or call 1-800-FDA-1088.

ENTYVIO is a prescription medicine used in adults for the treatment of:

*

This site is intended for use by U.S. residentsonly.

ENTYVIO is a trademark of Millennium Pharmaceuticals, Inc., registered with the U.S. Patent and Trademark Officeand is used under license by TakedaPharmaceuticalsU.S.A.,Inc. All other trademarks are the property of their respective owners.

2022Takeda Pharmaceuticals U.S.A.,Inc.

The links to third-party websites contained on this website are provided solely for your convenience. Takeda does not control the content contained on any third-party website linked from this website. Your activities at those websites will be governed by the policies and practices of those thirdparties.

Please select "Continue" if you wish to be taken to this third-party website.

Read more from the original source:
Ulcerative Colitis Infusion Therapy | ENTYVIO (vedolizumab)